April 1 - 3, 2020
Salt Lake City, Utah, USA
2020 Cholangiocarcinoma Foundation Annual Conference
The 2020 Conference will build upon the foundation laid at this year’s meeting as key opinion leaders both nationally and internationally, come together to collaborate and exchange knowledge. The program will seek to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma by:
Increasing the knowledge and understanding of attendees about key issues central to the prevention, diagnosis, treatment, and cure for cholangiocarcinoma
A New Perspective
Identifying gaps and gathering consensus on rapidly changing advances in basic, translational, and clinical research
Stimulating interdisciplinary cross-cooperation and sharing best practices by developing, strengthening, and supporting collaborations
Fostering dialogue and inspiring innovation across the world
Further, because patients living with cholangiocarcinoma have a direct stake in their own medical care and are in a unique position to provide input, CCF has expanded its Annual Conference to include programming that addresses questions and concerns that are important to patients and their families. Patients and caregivers—having experienced the disease firsthand—will be invited to learn about cholangiocarcinoma, share their personal experiences, and contribute to future efforts to further cholangiocarcinoma research.
Who Should Attend?
Who Should Attend?
- Nurses specializing in oncology, intensive care, and palliative care
- Pharmaceutical Companies
- Government Regulators
- Patients, Caregivers and others invested in the field of cholangiocarcinoma
Funding for this conference was made possible (in part) by 1R13CA246934 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.